Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 5/20 | 0.61 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.61 |
| ▸ | CHRNA1 | P02708 | 2/20 | 0.61 |
| ▸ | CHRNG | P07510 | 2/20 | 0.61 |
| ▸ | CHRNB1 | P11230 | 2/20 | 0.61 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.61 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.61 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.61 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.61 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.61 |
| ▸ | CHRND | Q07001 | 2/20 | 0.61 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.61 |
| ▸ | HRH1 | P35367 | 1/20 | 0.61 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.61 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.61 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.59 |
| ▸ | BLM | P54132 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2070613 | 1.00 | SLC6A2 (0.61) | SLC6A2SLC6A3CHRNA1CHRNGCHRNB1 | |
| SCHEMBL2599159 | 1.00 | SLC6A2 (0.61) | SLC6A2SLC6A3CHRNA1CHRNGCHRNB1 | |
| SCHEMBL29848384 | 1.00 | SLC6A2 (0.61) | SLC6A2SLC6A3CHRNA1CHRNGCHRNB1 | |
| SCHEMBL8159886 | 0.86 | SLC6A2 (0.63) | SLC6A2SLC6A3CHRNA1CHRNGCHRNB1 | |
| SCHEMBL11769927 | 0.85 | SLC6A2 (0.61) | SLC6A2SLC6A3CHRNA1CHRNGCHRNB1 | |
| SCHEMBL10305470 | 0.85 | SLC6A2 (0.61) | SLC6A2SLC6A3CHRNA1CHRNGCHRNB1 | |
| SCHEMBL5256414 | 0.85 | SLC6A2 (0.61) | SLC6A2SLC6A3CHRNA1CHRNGCHRNB1 | |
| SCHEMBL31268571 | 0.85 | SLC6A2 (0.61) | SLC6A2SLC6A3CHRNA1CHRNGCHRNB1 | |
| SCHEMBL633225 | 0.83 | SLC6A2 (0.59) | SLC6A2SLC6A3CHRNA1CHRNGCHRNB1 | |
| SCHEMBL3852863 | 0.83 | SLC6A2 (0.59) | SLC6A2SLC6A3CHRNA1CHRNGCHRNB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9527823-B2 | Hydroxybupropion analogues for treating drug dependence | RESEARCH TRIANGLE INSTITUTE (US) | 2016-12-27 | — | — | US | disclosed |
| EP-2571859-B1 | 1-PHENYLMORPHOLINE DERIVATIVES AS HYDROXYBUPROPION ANALOGUES FOR TREATING DRUG DEPENDENCE | RES TRIANGLE INST (US) | 2015-07-22 | — | — | EP | disclosed |
| US-20150141416-A1 | HYDROXYBUPROPION ANALOGUES FOR TREATING DRUG DEPENDENCE | RESEARCH TRIANGLE INSTITUTE | 2015-05-21 | — | — | US | disclosed |
| US-8906908-B2 | Hydroxybupropion analogues for treating drug dependence | RESEARCH TRIANGLE INSTITUTE (US) | 2014-12-09 | — | — | US | disclosed |
| US-20130150357-A1 | HYDROXYBUPROPION ANALOGUES FOR TREATING DRUG DEPENDENCE | RESEARCH TRIANGLE INSTITUTE (US) | 2013-06-13 | — | — | US | disclosed |
| EP-2571859-A2 | HYDROXYBUPROPION ANALOGUES FOR TREATING DRUG DEPENDENCE | Research Triangle Institute (US) | 2013-03-27 | — | — | EP | disclosed |
| WO-2011146821-A2 | 1 - PHENYLMORPHOLINE DERIVATIVES AS HYDROXYBUPROPION ANALOGUES FOR TREATING DRUG DEPENDENCE | RESEARCH TRIANGLE INSTITUTE (US) | 2011-11-24 | — | — | WO | disclosed |
| EP-1759701-B1 | Buproprion Metabolites for treating dementia and other cerebrovascular disorders | SEPRACOR INC (US) | 2010-12-22 | — | — | EP | disclosed |
| EP-1759701-B1 | Buproprion Metabolites for treating dementia and other cerebrovascular disorders | SEPRACOR INC (US) | 2010-12-22 | — | — | EP | disclosed |
| EP-1259243-B2 | BUPROPION METABOLITES AND METHODS OF THEIR SYNTHESIS AND USE | SEPRACOR INC (US) | 2010-07-21 | — | — | EP | disclosed |
| EP-1759701-A2 | Buproprion Metabolites and Methods of Their Synthesis and Use. | Sepracor, Inc. (US) | 2007-03-07 | — | — | EP | disclosed |
| EP-1259243-B1 | BUPROPION METABOLITES AND METHODS OF THEIR SYNTHESIS AND USE | SEPRACOR INC (US) | 2006-06-28 | — | — | EP | disclosed |
| US-20060058300-A1 | Intermediates of bupropion metabolites synthesis | SEPRACOR INC. | 2006-03-16 | — | — | US | disclosed |
| EP-1602369-A2 | Bupropion Metabolites and Methods of their Synthesis and Use | Sepracor, Inc. (US) | 2005-12-07 | — | — | EP | disclosed |
| EP-1259243-A2 | BUPROPION METABOLITES AND METHODS OF THEIR SYNTHESIS AND USE | SEPRACOR, INC. (US) | 2002-11-27 | — | — | EP | disclosed |
| US-20020052341-A1 | Bupropion metabolites and methods of their synthesis and use | SEPRACOR INC. | 2002-05-02 | — | — | US | disclosed |
| US-20020052340-A1 | Bupropion metabolites and methods of their synthesis and use | JERUSSI THOMAS P (US) | 2002-05-02 | — | — | US | disclosed |
| US-6342496-B1 | BRAIN DISORDERS | SEPRACOR INC. | 2002-01-29 | — | — | US | disclosed |
| US-6337328-B1 | TREATMENT OF SEXUAL DYSFUNCTION WITH 2-(3-CHLOROPHENYL)-2-HYDROXY-3,5,5-TRIMETHYL-MORPHOLINOL, 1-(3-CHLOROPHENYL)-2-((1,1-DIMETHYLETHANOL)AMINO)-1-PROPANOL, AND | SEPRACOR, INC. | 2002-01-08 | — | — | US | disclosed |
| WO-2001062257-A2 | BUPROPION METABOLITES AND METHODS OF THEIR SYNTHESIS AND USE | SEPRACOR INC. (US) | 2001-08-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020052341-A1 | Bupropion metabolites and methods of their synthesis and use | MAOB, MAOA, HTR5A | SLC6A2 6/4885SLC6A3 10/4885CHRNA1 86/4885 |
| US-20060058300-A1 | Intermediates of bupropion metabolites synthesis | MAOB, MAOA, SLC18A2 | SLC6A2 7/4885SLC6A3 10/4885CHRNA1 111/4885 |
| US-20130150357-A1 | HYDROXYBUPROPION ANALOGUES FOR TREATING DRUG DEPENDENCE | SLC6A2, SLC6A3, HTR3B | SLC6A2 1/4885SLC6A3 2/4885CHRNA1 24/4885 |
| US-20150141416-A1 | HYDROXYBUPROPION ANALOGUES FOR TREATING DRUG DEPENDENCE | SLC6A2, SLC6A3, HTR3B | SLC6A2 1/4885SLC6A3 2/4885CHRNA1 24/4885 |
| US-20020052340-A1 | Bupropion metabolites and methods of their synthesis and use | MAOB, MAOA, HTR5A | SLC6A2 4/4885SLC6A3 11/4885CHRNA1 76/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.